Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT03625102
PHASE2

A Randomized, Double-Blind Trial of Antroquinonol in Patients With Chronic Hepatitis B

Sponsor: Golden Biotechnology Corporation

View on ClinicalTrials.gov

Summary

Hepatitis B virus infection is a worldwide disease and is still the most common cause of hepatocellular carcinoma (HCC).Existing treatments for hepatitis B infection have various side-effects including renal toxicity and drug resistance or failure.

Official title: A Randomized, Double-Blind, Dosing-Ranging, Placebo-controlled Trial of Antroquinonol in Patients With Chronic Hepatitis B

Key Details

Gender

All

Age Range

20 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2018-02-12

Completion Date

2023-06-16

Last Updated

2026-10-19

Healthy Volunteers

No

Conditions

Interventions

DRUG

Antroquinonol

Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.

OTHER

placebo

The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects

Locations (1)

Chung Shan Medical University Hospital

Taichung, Taiwan, Taiwan